CRISPR QC is at the forefront of enhancing gene editing efficiency through its innovative CRISPR Analytics Platform™, which provides real-time insights into critical aspects of the CRISPR workflow. The platform enables researchers to monitor Ribonucleoprotein (RNP) formation, DNA target binding kinetics, and cleavage activity, allowing for the optimization of gRNA design and RNP assembly. By directly measuring nucleic acid-protein interactions, the technology helps identify the most effective gRNA and optimize conditions before proceeding to costly sequencing and screening experiments. This capability significantly reduces troubleshooting time and enhances productivity in gene editing projects.

Additionally, CRISPR QC's CLEAVE technology offers highly sensitive detection of CRISPR-Cas cleavage activity in real-time, empowering researchers to quantify the efficiency of gene editing processes. The platform's ability to provide accurate and reproducible data facilitates informed decision-making, ultimately accelerating breakthroughs in genetic engineering. By leveraging these advanced technologies, CRISPR QC aims to maximize CRISPR efficiency, improve accuracy, and reduce costs associated with iterative screening, thereby streamlining the overall gene editing workflow for researchers.

United States

Here at CRISPR QC, we empower scientists using CRISPR to solve the world's great challenges by providing the key cornerstones of information and insight fundamental to realizing the full potential of CRISPR.

CRISPR QC

Company Details